<DOC>
	<DOCNO>NCT01584713</DOCNO>
	<brief_summary>The purpose study determine safety Stromal Vascular Fraction ( SVF ) treatment enterocutaneous fistula .</brief_summary>
	<brief_title>Stromal Vascular Fraction ( SVF ) Treatment Enterocutaneous Fistula ( HULPUTC )</brief_title>
	<detailed_description>SF-12 Test</detailed_description>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Intestinal Fistula</mesh_term>
	<criteria>Signed informed consent Enterocutaneous fistula Men woman 18 year old . Good general state health accord finding clinical history physical examination Presence severe proctitis dominant active luminal disease require immediately therapy Patients abscess unless complete toilet area drainage collection absence abscess collection confirm prior treatment start Patients history abuse alcohol addictive substance 6 month prior inclusion Patients malignant tumor , except basal cell cutaneous squamous cell carcinoma , patient prior history malignant tumor , unless neoplastic disease remission previous 5 year Patients cardiopulmonary disease , opinion investigator , unstable sufficiently serious exclude patient study . Patients type medical psychiatric disease , opinion investigator , could ground exclusion study Patients congenital acquire immunodeficiency . HIV , HBV , HCV treponema infection , whether active latent Patients suffer major surgery severe trauma prior 6 month Pregnant breastfeed woman Patients currently receive , receive within 1 month prior enrollment clinical trial , investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Enterocutaneous fistula</keyword>
	<keyword>Adipose Derived Stem Cells</keyword>
</DOC>